EQL Pharma AB (OSTO:EQL) EPS without NRI: kr0.42 (TTM As of Mar. 2026)


OSTO:EQL EQL Pharma AB OSTO:EQL
42 GF Score
Price kr23.75
! 4 Warning Signs
View Full Analysis

What is EQL Pharma AB EPS without NRI?

EQL Pharma AB OSTO:EQL 42 EPS without NRI is kr0.42 as of Mar. 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 786 Drug Manufacturers companies, EQL Pharma AB ranks worse than 88.42% on this metric.

EQL Pharma AB's earnings per share without non-recurring items for the three months ended in Mar. 2026 was kr-0.13. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.42.

During the past 12 months, EQL Pharma AB's average earnings per share (NRI) Growth Rate was -70.80% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -26.10% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 3.70% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for EQL Pharma AB's EPS without NRI or its related term are showing as below:

OSTO:EQL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.1   Med: 17.95   Max: 123.6
Current: -26.1

During the past 13 years, EQL Pharma AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 123.60% per year. The lowest was -26.10% per year. And the median was 17.95% per year.

OSTO:EQL's 3-Year EPS without NRI Growth Rate is ranked worse than
88.42% of 786 companies
in the Drug Manufacturers industry
Industry Median: 9.6 vs OSTO:EQL: -26.10

EQL Pharma AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr-0.13. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.42.

EQL Pharma AB's EPS (Basic) for the three months ended in Mar. 2026 was kr-0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.43.


EQL Pharma AB  (OSTO:EQL) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


EQL Pharma AB EPS without NRI Related Terms


EQL Pharma AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB EPS without NRI Chart

EQL Pharma AB Annual Data
Trend Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.09 1.04 0.72 1.44 0.42

EQL Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.33 -0.11 0.33 -0.13

OSTO:EQL vs ZTS, UTHR: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQL Pharma AB PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's PE Ratio without NRI falls into.


OSTO:EQL
42GF Score
EQL Pharma AB OSTO:EQL
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of kr0.42 mean?
EQL Pharma AB (OSTO:EQL) has a EPS without NRI of kr0.42 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on EQL Pharma AB and its competitors. According to the industry distribution chart, EQL Pharma AB ranks #695 out of 786 companies in the Drug Manufacturers industry, placing it in the top 88.4%.
Is EQL Pharma AB's EPS without NRI too high?
EQL Pharma AB's current EPS without NRI is kr0.42. Based on the distribution chart, EQL Pharma AB ranks #695 out of 786 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #695 out of 786 companies for EPS without NRI. This places EQL Pharma AB in the lower half of its industry. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current EPS without NRI is kr0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current EPS without NRI of kr0.42. The current EPS without NRI is kr0.42. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current EPS without NRI is kr0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Other Exchanges 7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score

Get the complete analysis for OSTO:EQL

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.75
Price